In addition to a thorough evaluation of the current diagnosis and management of celiac disease (CeD), five pipeline product profiles...
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day...
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat,...
Spherix finds that perceptions related to efficacy appear to be impacting the new, more convenient formulation of the α4β7 integrin...
Aside from an in-depth evaluation of the current diagnosis and management of NAFLD/NASH, ten pipeline product profiles were evaluated by...
Findings from the 16th wave of Spherix Global Insights’ COVID-19 research indicate that telemedicine is firmly entrenched, industry interaction remains...
Six pipeline product profiles were evaluated by current inflammatory bowel disease treaters to assess strengths, weaknesses, and potential prescribing levels...
According to Spherix Global Insights, specialists in dermatology, gastroenterology, nephrology, neurology, and rheumatology have little interest in engaging with industry,...
The Launch Dynamix™ service includes current tracking of Cosentyx (Novartis) and Taltz (Eli Lilly) in non-radiographic axial spondyloarthritis, Kesimpta (Novartis)...
Entyvio SC and Remsima SC have experienced noteworthy uptake since their launches in 2020 and are positioned for continued success...
Infliximab and adalimumab biosimilars continue to increase their presence in ulcerative colitis and Crohn’s disease therapy switching, while Entyvio SC...
Spherix Global Insights and Fraser Healthcare are partnering to shed light in this evolving landscape with a new service that...
